The modified ITT (mITT) population consisted of all participants who were randomized, vaccinated, and provided at least 1 day of complete data on the symptom diary form. Figure 2. Difference in Proportions for Any Severe, Local, or Systemic Reactions From Recombinant Zoster Vaccine (RZV) Dose ...
Then, a focus group discussion took place among five policy makers and experts to screen, rank and reduce the 7 extracted attributes and levels that fit the influenza vaccine based on this study purpose. Four attributes were eventually selected: 1) vaccination setting; 2) appointment mode; 3) ...
different influenza vaccines are given to children aged < 3 years and ≥ 3 years [13]. The vaccine given to children aged < 3 years is named the “children
17. However, antigenic drift of HA and NA proteins results in reduced efficacy of these vaccines, requiring near annual updates of the influenza vaccine strains18. In the absence of neutralizing antibodies
and assuming population-wide rates of influenza vaccine uptake in the Netherlands, only 3% of the ACS individuals, who importantly were all HIV-seronegative, would be expected to be vaccinated. Combined with the similarity in antibody baseline titres and waning rates when comparing adults below and...
The race toward a universal influenza vaccine: front runners and the future directions. Antiviral Res. 2023;210:105505. 8. Lamb RA, Lai CJ, Choppin PW. Sequences of mRNAs derived from genome RNA segment 7 of influenza virus: colinear and interrupted mRNAs code for overlapping proteins. Proc...
Full vaccination status was defined as 2 doses, and partial status was defined as having 1 dose of an approved vaccine, which corresponded to the established provincial criteria during the study period that was before the availability of third and fourth booster doses. Comorbidities were identified...
Current antigenic targets for influenza vaccine development are either highly immunogenic epitopes of high variability or conserved epitopes of low immunogenicity. This requires continuous update of the variable epitopes in the vaccine formulation or boo
Influenza A viruses pose a significant threat globally each year, underscoring the need for a vaccine- or antiviral-based broad-protection strategy. Here, we describe a chimeric monoclonal antibody, C12H5, that offers neutralization against seasonal and
Volume 56, Issue 9, 12 September 2023, Pages 2036-2053.e12ArticleLoss of CD4+ T cell-intrinsic arginase 1 accelerates Th1 response kinetics and reduces lung pathology during influenza infection Author links open overlay panelErin E. West 1, Nicolas S. Merle 1, Marcin M. Kamiński 2, Gustavo...